[Phase II study of mitoxantrone in advanced breast cancer].
A phase II study of mitoxantrone in cases of advanced breast cancer was conducted by a cooperative study group involving 7 institutions. Mitoxantrone was administered at doses of 10-12 mg/m2 at 3-4-week intervals. A total of 36 patients were entered and 31 were evaluable. There were 4 CRs (13%) and 3 PRs (10%) with an overall response rate of 23% and the durations of responses were between 6 and 25 weeks. Leukopenia was a dose-limiting effect of toxicity and occurred in all patients, while gastrointestinal toxicity and alopecia were mild.
M
M
Ogawa
K
K
Kubo
T
T
Tominaga
Y
Y
Nomura
K
K
Ota
M
M
Yoshida
T
T
Taguchi
A
A
Hoshino
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D008942:Mitoxantrone; D009362:Neoplasm Metastasis
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone